skin infections

Delafloxacin (Baxdela) for Acute Bacterial Skin Infections
Delafloxacin (Baxdela) for Acute Bacterial Skin InfectionsDelafloxacin (Baxdela) for treatment of acute bacterial skin and skin structure infections including cellulitis, wound infection, major cutaneous abscess, and burn infection.
Antimicrobials approved for children’s skin infectionsFor the first time in a decade, there are antibiotics newly approved for use in children with skin and skin structure infections that do not respond to conventional treatment.
Off-patent antibiotics fight community-associated MRSANational Institutes of Health researchers found that clindamycin and trimethoprim–sulfamethoxazole (TMP-SMX) work equally well to treat uncomplicated skin infections, including cellulitis and abscesses.
Diagnosing and Treating Acute Bacterial Skin and Skin Structure InfectionsCME video and activity from The Doctor's Channel, featuring speaker David A. Talan, MD.
Infection-causing bacteria found in hidradenitis suppurativa lesionsBacteria responsible for causing skin and soft tissue infections has been found in hidradenitis suppurativa lesions, results of a recent study indicate.
Coexisting problems impede identification/treatment of onychomycosis
Coexisting problems impede identification/treatment of onychomycosisTough cases of onychomycosis frequently include complicating factors such as psoriasis, onycholysis and non-dermatophyte infections, an expert says.
FDA warns of contaminated tattoo inkContaminated tattoo ink that was recalled in July may have reached distributors and poses the potential for skin infections and other health problems, the Food and Drug Administration has warned.
FDA approves another antibiotic for hard-to-treat skin infectionsFDA has approved oritavancin (Orbactiv, The Medicines Company) for injection for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible designated Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA).
FDA approves oritavancin for skin infectionsFDA has approved oritavancin (Orbactiv, The Medicines Company) for injection for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible designated Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA).
FDA drug approvals-August 2014FDA actions in brief, complete response, fast-track designation, priority review, orphan drug designations, first-time generic approval